Seasoned pharmaceutical marketing leader brings extensive experience in brand management, sales strategy, and digital engagement to the expanded leadership role
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
